TY - JOUR
T1 - Pulmonary and psychosocial findings at enrollment in the ACCESS study
AU - Yeager, Henry
AU - Rossman, Milton D.
AU - Baughman, Robert P.
AU - Teirstein, Alvin S.
AU - Judson, Marc A.
AU - Rabin, David L.
AU - Iannuzzi, Michael C.
AU - Rose, Cecile
AU - Bresnitz, Eddy A.
AU - DePalo, Louis
AU - Hunninghake, Gary
AU - Johns, Carol J.
AU - McLennan, Geoffrey
AU - Moller, David R.
AU - Newman, Lee S.
AU - Rybicki, Benjamin
AU - Weinberger, Steven E.
AU - Wilkins, Patricia C.
AU - Cherniack, Rueben
PY - 2005/6/1
Y1 - 2005/6/1
N2 - Aim: To assess lung involvement and the association of demographic and psychosocial factors with respiratory health in 736 persons with sarcoidosis at enrollment in A Case Control Etiologic Study of Sarcoidosis (ACCESS). Methods: 736 patients with biopsy diagnosis of sarcoidosis within 6 months of enrollment were studied at 10 US centers. Lung involvement was evaluated by chest radiography, spirometry and dyspnea questionnaire. Demographics, number of involved extrathoracic organ systems, comorbidities, and health-related quality of life (HRQL) were assessed. Results: 95% of patients had lung involvement. 8% were Scadding Stage 0, 40% I, 37% II, 10% III, and 5% IV. 51% reported dyspnea. Increasing radiographic lung stage was associated with decreasing Forced Vital Capacity (FVC) (p < 0.01). Patients with higher stages had more airways obstruction and dyspnea. 46% of cases and 27% of controls had Center for Epidemiologic Studies Depression Scale (CES-D) scores of 9 or greater, (p < 0.001). Age ≥ 40, African-American race, body mass index ≥ 30kg/m 2, and CES-D scores > 9 were associated with decreased FVC and greater dyspnea. Impaired spirometry and greater dyspnea were associated with poorer quality of life. Conclusion: A "global" approach to the sarcoidosis patient, including careful assessment of dyspnea and health related quality of life, as well as of lung function and radiographic changes, and any extrathoracic involvement, is important, not only in management of the individual patient, but should also prove beneficial in assessing outcomes in clinical trials in the future.
AB - Aim: To assess lung involvement and the association of demographic and psychosocial factors with respiratory health in 736 persons with sarcoidosis at enrollment in A Case Control Etiologic Study of Sarcoidosis (ACCESS). Methods: 736 patients with biopsy diagnosis of sarcoidosis within 6 months of enrollment were studied at 10 US centers. Lung involvement was evaluated by chest radiography, spirometry and dyspnea questionnaire. Demographics, number of involved extrathoracic organ systems, comorbidities, and health-related quality of life (HRQL) were assessed. Results: 95% of patients had lung involvement. 8% were Scadding Stage 0, 40% I, 37% II, 10% III, and 5% IV. 51% reported dyspnea. Increasing radiographic lung stage was associated with decreasing Forced Vital Capacity (FVC) (p < 0.01). Patients with higher stages had more airways obstruction and dyspnea. 46% of cases and 27% of controls had Center for Epidemiologic Studies Depression Scale (CES-D) scores of 9 or greater, (p < 0.001). Age ≥ 40, African-American race, body mass index ≥ 30kg/m 2, and CES-D scores > 9 were associated with decreased FVC and greater dyspnea. Impaired spirometry and greater dyspnea were associated with poorer quality of life. Conclusion: A "global" approach to the sarcoidosis patient, including careful assessment of dyspnea and health related quality of life, as well as of lung function and radiographic changes, and any extrathoracic involvement, is important, not only in management of the individual patient, but should also prove beneficial in assessing outcomes in clinical trials in the future.
KW - Health-related quality of life
KW - Pulmonary disease
KW - Sarcoidosis
UR - http://www.scopus.com/inward/record.url?scp=22544465274&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=22544465274&partnerID=8YFLogxK
M3 - Article
C2 - 16053031
AN - SCOPUS:22544465274
SN - 1124-0490
VL - 22
SP - 147
EP - 153
JO - Sarcoidosis Vasculitis and Diffuse Lung Diseases
JF - Sarcoidosis Vasculitis and Diffuse Lung Diseases
IS - 2
ER -